Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1148-1154

  Todenhöfer, Tilman ^a   Hennenlotter, Joerg ^a   Tews, Veronika ^a   Gakis, Georgios ^a   Aufderklamm, Stefan ^a   Kuehs, Ursula ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fluorescence in situ hybridization; Hematuria; Immunocytology; Nuclear matrix protein 22; Urine cytology; Urothelial carcinoma

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BIOPSY; BLADDER; BLADDER CATHETERIZATION; CARCINOMA IN SITU; CYSTOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT; URINE CYTOLOGY;

FLUORESCENCE IN-SITU HYBRIDIZATION; HEMATURIA; IMMUNOCYTOLOGY; NUCLEAR MATRIX PROTEIN 22; URINE CYTOLOGY; UROTHELIAL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; URINE; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 84884671506     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.10.011     Document Type: Article

References (35)

1. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality, and recurrence. J Urol 2000, 164:680-684.
2. Shariat S.F., Karam J.A., Lotan Y., et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008, 10:120-135.
3. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
4. Raitanen M.P., Aine R., Rintala E., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002, 41:284-289.
5. Budman L.I., Kassouf W., Steinberg J.R. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008, 2:212-221.
6. Schmitz-Drager B.J., Tirsar L.A., Schmitz-Drager C., et al. Role of immunocytology in the evaluation of patients with painless gross hematuria]. Urologe A 2010, 49:741-746.
7. Chiong E., Gaston K.E., Grossman H.B. Urinary markers in screening patients with hematuria. World J Urol 2008, 26:25-30.
8. Ponsky L.E., Sharma S., Pandrangi L., et al. Screening and monitoring for bladder cancer: Refining the use of nmp22. J Urol 2001, 166:75-78.
9. Raitanen M.P., Kaasinen E., Lukkarinen O., et al. Analysis of false-positive BTA stat test results in patients followed up for bladder cancer. Urology 2001, 57:680-684.
10. Atsu N., Ekici S., Oge O.O., et al. False-positive results of the NMP22 test due to hematuria. J Urol 2002, 167:555-558.
11. Shariat S.F., Marberger M.J., Lotan Y., et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006, 176:919-926. discussion 926.
12. Rathert P., Roth S., Soloway M.S., et al. Urinary cytology: Manual and atlas 1993, Springer-Verlag, Berlin, New York. 2nd ed.
13. Bubendorf L. Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma-fishing for the right catch. Acta Cytol 2011, 55:113-119.
14. Mian C., Maier K., Comploj E., et al. Ucyt+/immunocyt in the detection of recurrent urothelial carcinoma: An update on 1991 analyses. Cancer 2006, 108:60-65.
15. Papanicolaou G.N., Marshall V.F. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945, 101:519-520.
16. Riesz P., Lotz G., Paska C., et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 2007, 13:187-194.
17. Kipp B.R., Tyner H.L., Campion M.B., et al. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol 2008, 130:552-559.
18. Mian C., Pycha A., Wiener H., et al. A new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999, 161:1486-1489.
19. Greene K.L., Berry A., Konety B.R. Diagnostic utility of the immunocyt/ucyt+ test in bladder cancer. Rev Urol 2006, 8:190-197.
20. Henenlotter J., Witstruk M., Wagner V., et al. Impact of renal function on the diagnostic accuracy of urine-based tests for the detection of bladder cancer. J Urol 2011, 185:e497-e498.
21. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004, 172:1123-1126.
22. Britton J.P., Dowell A.C., Whelan P., et al. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992, 148:788-790.
23. Khan M.A., Shaw G., Paris A.M. Is microscopic hematuria a urological emergency?. BJU Int 2002, 90:355-357.
24. Saad A., Hanbury D.C., McNicholas T.A., et al. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002, 89:369-373.
25. Pesch B., Nasterlack M., Eberle F., et al. The role of hematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 2011, 108:546-552.
26. Karakiewicz P.I., Benayoun S., Zippe C., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006, 97:997-1001.
27. Tetu B., Tiguert R., Harel F., et al. Immunocyt/ucyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005, 18:83-89.
28. Mack D., Frick J. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guerin bacillus for superficial bladder cancer. Urol Int 1994, 52:204-207.
29. Messing E.M., Teot L., Korman H., et al. Performance of urine test in patients monitored for recurrence of bladder cancer: A multicenter study in the United States. J Urol 2005, 174:1238-1241.
30. Vriesema J.L., Atsma F., Kiemeney L.A., et al. Diagnostic efficacy of the immunocyt test to detect superficial bladder cancer recurrence. Urology 2001, 58:367-371.
31. Oge O., Kozaci D., Gemalmaz H. The BTA stat test is nonspecific for hematuria: An experimental hematuria model. J Urol 2002, 167:1318-1319. Discussion 1319-20.
32. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999, 162:53-57.
33. Miyanaga N., Akaza H., Ishikawa S., et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997, 31:163-168.
34. Wang X., Zhang K., Sun L., et al. Short interfering RNA directed against slug blocks tumor growth, metastasis formation, and vascular leakage in bladder cancer. Med Oncol 2010 Oct 30, [E-Pub ahead of print].
35. Eissa S., Ali-Labib R., Swellam M., et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (mmp-2 and mmp-9) and their inhibitor (timp-2) in urine. Eur Urol 2007, 52:1388-1396.